Implications of matrix effects in ultra-fast gradient or fast isocratic liquid chromatography with mass spectrometry in drug discovery.
In the analysis of biological samples it is important to reduce the risk of interferences from the matrix itself, other analytes, the dosing vehicle (commonly PEG), and from the MS/MS transitions used for the analysis. Rapid analysis is essential for drug discovery, and even though the requirements for separation may be minimized for speed, the integrity of the analysis is still dependent on the separation. This paper focuses on the potential for interferences from various endogenous and exogenous matrix components commonly encountered in quantitation of analytes and their metabolites from biological matrices. We demonstrate that neither high organic isocratic nor ballistic gradient ultra-fast HPLC show a clearly defined advantage in regards to complex biological matrices. The critical factor in the resolution of matrix interferences still remains in sample preparation.
Tiller
Philip R
PR
Drug Metabolism, Merck Research Laboratories, WP75-100, West Point, PA 19486, USA. philip_tiller@merck.com
Romanyshyn
Leslie A
LA
D000818:Animals; D001646:Bile / Q000737:chemistry; D001769:Blood; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D002853:Chromatography, Liquid / Q000379:methods*; D015507:Drugs, Investigational; D013058:Mass Spectrometry / Q000379:methods*; D011786:Quality Control; D051381:Rats; D013048:Specimen Handling; D014556:Urine / Q000737:chemistry
D015507:Drugs, Investigational